Teva Plan to Safeguard $4 Billion Drug Endangered by Ruling

Teva Pharmaceutical Industries Ltd.’s plan to switch patients to a longer-acting version of its Copaxone treatment suffered a setback as a U.S. court ruling gave the $4 billion drug less than a year of patent protection.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.